We are live on ! Find out more
CCM

Catalio Capital Management Portfolio holdings

AUM $479M
1-Year Est. Return 140.7%
This Fund
S&P 500
This Quarter Est. Return
+7.86%
1 Year Est. Return
+140.7%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$477M
AUM Growth
+$65.8M
Cap. Flow
+$35.2M
Cap. Flow %
7.38%
Top 10 Hldgs %
62.53%
Holding
49
New
12
Increased
8
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$24.1M
2
LLY icon
Eli Lilly
LLY
+$23.5M
3
BSX icon
Boston Scientific
BSX
+$23.2M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$18.9M
5
SLNO
Soleno Therapeutics
SLNO
+$18.6M

Top Sells

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$46.7M
2
SWTX
SpringWorks Therapeutics
SWTX
+$33.5M
3
VCYT icon
Veracyte
VCYT
+$22.6M
4
LIVN icon
LivaNova
LIVN
+$15M
5
INSP icon
Inspire Medical Systems
INSP
+$13.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1.07T
$42M 8.81%
53,916
+30,234
+128% +$23.5M
BBIO icon
2
BridgeBio Pharma
BBIO
$16.5B
$40.1M 8.4%
927,711
-35,172
-4% -$1.28M
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
$34.3M 7.2%
409,944
+248,982
+155% +$18.6M
ASND icon
4
Ascendis Pharma A/S
ASND
$16.7B
$31.1M 6.51%
179,926
-15,597
-8% -$2.54M
ISRG icon
5
Intuitive Surgical
ISRG
$121B
$30.8M 6.46%
56,674
+20,175
+55% +$10.5M
EW icon
6
Edwards Lifesciences
EW
$47.6B
$30.6M 6.41%
390,932
-44,656
-10% -$3.33M
GILD icon
7
Gilead Sciences
GILD
$161B
$25.2M 5.27%
+226,875
New +$24.1M
BSX icon
8
Boston Scientific
BSX
$65.8B
$24.6M 5.16%
+229,046
New +$23.2M
CYTK icon
9
Cytokinetics
CYTK
$11B
$19.9M 4.17%
601,439
+15,627
+3% +$544K
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.84B
$19.7M 4.13%
2,104,512
+370,811
+21% +$4.08M
TEVA icon
11
Teva Pharmaceuticals
TEVA
$35.9B
$19.6M 4.11%
+1,170,372
New +$18.9M
CORT icon
12
Corcept Therapeutics
CORT
$10.2B
$17.6M 3.68%
+239,125
New +$17.3M
NTRA icon
13
Natera
NTRA
$37.5B
$16.4M 3.45%
+97,297
New +$15.2M
ADPT icon
14
Adaptive Biotechnologies
ADPT
$3.56B
$16.3M 3.41%
1,396,445
+784,806
+128% +$7.13M
DNTH icon
15
Dianthus Therapeutics
DNTH
$5.68B
$13.9M 2.92%
746,527
-16,944
-2% -$318K
GPCR icon
16
Structure Therapeutics
GPCR
$3.49B
$13.9M 2.92%
670,575
-34,289
-5% -$754K
ADMA icon
17
ADMA Biologics
ADMA
$1.92B
$10.4M 2.18%
+569,704
New +$11.6M
HALO icon
18
Halozyme
HALO
$9.72B
$9.96M 2.09%
+191,529
New +$10.9M
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.65B
$7.76M 1.63%
+213,402
New +$7.69M
MLTX icon
20
MoonLake Immunotherapeutics
MLTX
$1.59B
$7.67M 1.61%
162,596
+47,980
+42% +$1.95M
PHAT icon
21
Phathom Pharmaceuticals
PHAT
$912M
$6.45M 1.35%
+672,290
New +$3.72M
QURE icon
22
uniQure
QURE
$2.68B
$5.82M 1.22%
417,443
-412,882
-50% -$5.55M
WGS icon
23
GeneDx Holdings
WGS
$1.75B
$5.68M 1.19%
+61,507
New +$4.83M
TARA icon
24
Protara Therapeutics
TARA
$226M
$4.93M 1.03%
1,626,370
+537,679
+49% +$1.85M
OM icon
25
Outset Medical
OM
$74.9M
$3.2M 0.67%
166,666
– –
1
2

Similar funds

FFG
Frisch Financial Group Melville, New York $478M AUM 16.28% 1-Year Est. Return
RFWA
RPg Family Wealth Advisory Burlington, Massachusetts $479M AUM 25.83% 1-Year Est. Return
SWM
Silverlake Wealth Management Williston, Vermont $479M AUM 17.75% 1-Year Est. Return
CMI
Clare Market Investments Dallas, Texas $478M AUM
TCM
Towneley Capital Management Laguna Hills, California $478M AUM 16.21% 1-Year Est. Return
LIM
Longfellow Investment Management Boston, Massachusetts $480M AUM 8% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return

Catalio Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Catalio Capital Management held 49 positions worth $477M, up 16% from $411M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Catalio Capital Management deployed $35.2M of net new capital in Q2 2025, opening 12 new positions and adding to 8 existing holdings. Its largest new stake was Gilead Sciences: 226,875 shares worth $25.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

On the sell side, the largest reduction was Septerna Inc, an estimated $6.01M trimmed.

  • Catalio Capital Management's largest Q2 2025 buy was Gilead Sciences: 226,875 shares worth $25.2M.
  • Catalio Capital Management added most to Eli Lilly in Q2 2025, an estimated $23.5M increase.
  • Catalio Capital Management's biggest Q2 2025 reduction was Septerna Inc, cutting an estimated $6.01M.
  • Catalio Capital Management fully exited Becton Dickinson in Q2 2025, selling an estimated $46.7M.
  • Catalio Capital Management's ten largest holdings make up 63% of its $477M portfolio in Q2 2025.
  • Catalio Capital Management opened 12 new positions and closed 9 in Q2 2025.
  • Catalio Capital Management's portfolio value rose 16% quarter-over-quarter to $477M.

Based on Catalio Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.